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Abstract
 .Hexokinase ATP: D-hexose 6-phosphotransferase, EC 2.7.1.1; HK deficiency is a rare disease where the predominant
clinical effect is nonspherocytic hemolytic anemia. We have previously shown that the only patient for which hexokinase
deficiency has been so far investigated at molecular level is a double heterozygote carrying a T1667 “C substitution on one
 .HK type I allele and a 96 bp deletion concerning nucleotides 577 to 672 in the HK cDNA sequence in the other allele. To
investigate whether these mutations found in the patient with the hexokinase variant referred to as ‘HK-Melzo’ could be
associated with hexokinase deficiency, we have expressed in E. coli the wild-type human hexokinase type I and two
different mutants carrying the T“C nucleotide substitution at position 1667 and the nt 577–672 deletion, respectively.
Wild-type human recombinant hexokinase is expressed in bacterial cells as a soluble catalytically active enzyme that, upon
purification to homogeneity, exhibited the same kinetic properties of human placenta hexokinase type I. Both mutant
hexokinases were also expressed as soluble recombinant proteins under the same conditions, but they showed an impaired
catalytic activity with respect to the wild-type enzyme. In particular, the T1667 “C substitution, causing the amino acid
change from Leu529 to Ser, is responsible for the complete loss of the hexokinase catalytic activity, while the 96 bp deletion
causes a drastic reduction of the hexokinase activity. Taken together, both mutations explain the hexokinase deficiency
found in the patient with the ‘HK-Melzo’ variant. q1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hexokinase in mammalian cells ATP: D-hexose
.6-phosphotransferase, EC 2.7.1.1; HK is the first
enzyme of the glycolytic pathway that commits glu-
cose to catabolism by catalyzing its phosphorylation
 .to glucose 6-phosphate Glc 6-P with MgPATP as
phosphate donor and is considered one of the rate-
w xlimiting enzymes of glycolysis 1 . Four different
isozymes named type I, II, III and IV or glucokinase,
) Corresponding author. Fax: q39 722 320188.
which vary in their tissue distribution, kinetic and
molecular properties are present in mammalian tis-
w xsues 2 . Among all these, HK type I is the predomi-
nant glucose phosphorylating activity in those tissues
which share a strict dependence upon glucose utiliza-
tion for their physiological functions such as brain
tissue, erythrocytes, platelets, lymphocytes and fi-
w xbroblasts 3–6 . Hexokinase deficiency is a rare dis-
ease where the predominant clinical effect is non-
spherocytic hemolytic anemia. The reasons why this
genetically determined molecular lesion has only this
consequence at clinical level are still unknown. Only
14 cases of hexokinase deficiency have been de-
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w xscribed so far 7 , two of which have been studied in
w xour laboratory 8–10 : in one case, designated ‘HK-
Melzo’, the HK type I cDNA from the patient with
hemolytic anemia was also characterized at molecular
level. PCR amplification and sequence of the entire
‘HK-Melzo’ cDNA revealed the presence of a dele-
tion and of a single nucleotide substitution, both in
w xheterozygous form 11 . We thus concluded that the
patient carried a point mutation at nt 1667 on one HK
 529allele which causes the amino acid substitution Leu
.to Ser and a 96 bp deletion on the other allele and
was therefore unable to produce any wild-type fully
catalytically active hexokinase type I. To investigate
whether both the nucleotide substitution at position
1667 and the 96 bp deletion were responsible for the
hexokinase deficiency in the patient, we have now
generated two hexokinase mutants carrying the point
mutation and the 96 bp deletion, respectively. Ex-
pression of wild-type recombinant human hexokinase
and the two mutants confirmed that both mutations
impaired, although to a different extent, the hexoki-
nase catalytic activity.
2. Materials and methods
2.1. Materials
lhHEX-15 clone was from ATCC American Type
.Culture Collection, MD . pET expression vectors and
 .E. coli strain BL21 DE3 were purchased from No-
 .vagen Madison, WI . ‘Sculptore in vitro mutagene-
sis system’ and M13mp19 RF DNA were from
Amersham as well as ‘Sequenase Version 2.0 DNA
 . w 35 xSequencing Kit’ USB and a S dATP used for
DNA sequence analysis. Mutagenic primers and
Phenyl Sepharose CL-4B were obtained from Phar-
macia LKB Biotechnology. PVDF membranes used
for solid phase assay and Goat anti rabbit IgG
horseradish peroxidase conjugate were purchased
from Bio Rad.
2.2. Synthesis of ‘HK-Melzo’ cDNA
The cDNA of ‘HK-Melzo’ was prepared by re-
verse transcription of mRNA purified from a lympho-
blastic cell line derived from the lymphocytes of the
w xpatient, as detailed in 11 .
2.3. Construction of wild-type human hexokinase type
I expression ˝ector
The construction of the expression vector for
wild-type human hexokinase type I was performed
essentially as recently described by Fromm and
w xcoworkers 12 for the human brain hexokinase, with
slight modifications. The cDNA sequence for expres-
sion of wild-type HK I was obtained from the lamb-
 .dahHEX-15 clone purchased from ATCC, MD . This
clone includes nucleotides 38-3598, encoding a com-
plete 917 amino acid protein, and moreover contains
43 bp 5X untranslated and 765 bp 3X untranslated
w xsequence 13 . The 316 bp EcoRI fragment of
lhHEX-15 containing the amino terminal 91 codons
of the HK I open reading frame was ligated into the
-  .Bluescript KS plasmid Stratagene previously cut
 y .with EcoRI. The resultant plasmid KS -316 bp HK
was submitted to the oligonucleotide directed site-
specific mutagenesis procedure to create a NdeI
recognition site at the ATG start codon of the HK I
open reading frame, exactly as described by Liu, F. et
w xal. 12 . The 272 bp NdeI- EcoRI fragment obtained
by digestion of the mutant plasmid was gel-purified
and then ligated into the pET-3a expression vector
 .Novagen . The 3245 bp fragment, containing nt
354-3598 of HK type I cDNA, was isolated from the
 .  .  .Fig. 1. Construction of pET-3a HK a and pET-3a HKm1667 b, c expression vectors. a To construct the pET-3a HK expression
vector the following steps were performed: the pET-3a plasmid was digested with NdeI and EcoRI and then ligated with the 272 bp
 .  .NdeI-EcoRI fragment of HK I cDNA containing nt 82-353 . The resultant pET-3a HK 82-353 plasmid was linearized with EcoRI and
 .subsequently ligated with the 3245 bp EcoRI fragment of HK I cDNA concerning nt 354-3598 to obtain the pET-3a HK expression
 .  529 .vector. b To construct the mutant Leu to Ser expression vector the 4302 bp XbaI-PstI fragment, containing the entire cDNA was
cut from pET-3a HK and subcloned into the M13mp19 to perform the site-directed mutagenesis T1667 “C using the mutagenic primer
 . 1667HK 1656M. c To obtain the final construct named pET-3a HKm1667 the 2904 bp NcoI-PstI fragment containing the desired T “C
substitution was cut from the M13 mutant RF DNA and then recloned into the plasmid pET-3a HK from which the wild-type NcoI-PstI
fragment had been removed. Further details of these procedures are reported in Section 2.
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same lhHEX-15 clone by digestion with EcoRI,
followed by gel purification. This 3245 bp EcoRI
fragment, comprising the coding region for amino
acid residues 92-917 as well as the 3X untranslated
region, was then ligated into the pET-3a plasmid that
already contained nt 82-353 of the HK N-terminal
sequence. The maintenance of the correct orientation
of the two partial HK I cDNA fragments was verified
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by nucleotide sequence analysis. The expression vec-
tor with the full-length HK type I cDNA was named
pET-3a HK and the scheme used for its construction
is shown and detailed in Fig. 1a.
( 529 )2.4. Construction of the mutant Leu to Ser hex-
okinase type I expression ˝ector
Site-directed mutagenesis at nt 1667 was per-
formed using the ‘Sculptore in vitro mutagenesis
system’ from Amersham, according to the instruc-
tions of the manufacturers and essentially as de-
w xscribed by Zeng, C. and Fromm, H.J. 14 . Briefly,
the expression plasmid pET-3a HK was digested with
the restriction enzymes XbaI and PstI. A 4302 bp
XbaI-PstI fragment, containing the entire HK cDNA
insert plus flanking regions of the vector, was sub-
cloned into the polylinker region of M13mp19 at the
XbaI and Pst I sites and was used as a template to
make the site-directed change. For the T“C substi-
tution at nt 1667 the 24-mer long mutagenic primer,
designated HK 1656M, was 5X-TGGTGACTTCTCG-
GCCCTGGATCT-3X. The single strand DNA from
M13 transformants was sequenced in order to iden-
tify the desired T1667 “C substitution and also to
exclude the presence of random mutations in the
entire portion of the open reading frame submitted to
 .the mutagenesis protocol Fig. 1b . DNA sequencing
was carried out by dideoxy chain termination method
w xof Sanger et al. 15 , using Sequenase Version 2.0. In
order to transfer the mutant to the expression plasmid
 .pET-3a Fig. 1c a replicative form DNA of M13
mutant was cut at two unique restriction sites with
NcoI and Pst I. The 2904 bp NcoI-PstI fragment was
gel-purified and then recloned into the plasmid pET-
3a HK from which the wild-type NcoI-PstI fragment
had been removed. The desired T“C mutation in
the expression plasmid termed pET-3a HKm1667
was reconfirmed by DNA sequence analysis.
2.5. Construction of the 96 bp deleted hexokinase
type I expression ˝ector
To express in E. coli a mutant recombinant hexok-
inase containing the nt 577-672 deletion, the follow-
 .ing steps were performed: 1 a PCR amplification of
‘HK-Melzo’ cDNA which gave two PCR products in
the same ratio: the first one was 697 bp long from nt
.390 to nt 1087 and the second one was 601 bp long
because it contained the 96 bp deletion. The couple
of primers used for this amplification were: HK 3
 . X Xsense 5 -GAATGTTCACATGGAGTCCGAG-3
 . Xand HK 6 antisense 3 -GAGTGGGCTCCCT-
X  .TCAAATTGT-5 . 2 The 601 bp fragment was gel-
purified, ligated into the TA cloning vector Invitro-
.gen and then subjected to DNA sequence analysis.
 .3 The cloned deleted insert was cut with Bcl I
which cleaves at bases 462 and 764 and the resultant
206 bp long fragment was ligated with pET-3d
NH HK plasmid from which the wild-type 302 bp2
 .Bcl I undeleted fragment had been removed Fig. 2a .
 .4 The expression plasmid obtained designated pET-
3d NH HKdel was digested at two unique restriction2
sites with XbaI and NcoI: the 1302 bp fragment
obtained, containing the nt 577–672 deletion, was
then recloned into the pET-3a HK expression vector
from which the corresponding wild-type undeleted
 .  .fragment 1398 bp long had been removed Fig. 2b .
The 96 bp deletion in the final expression plasmid
named pET-3a HKdel was verified by DNA sequence
analysis.
2.6. Expression of wild-type and mutant hexokinase
proteins
The recombinant plasmids pET-3a HK, pET-3a
HKm1667 and pET-3a HKdel were transformed into
 .the E. coli strain BL21 DE3 to overexpress the
wild-type and mutant hexokinase proteins. The induc-
 .Fig. 2. Construction of the pET-3a HKdel expression vector. a The 601 bp deleted PCR product obtained by amplifying the ‘HK-Melzo’
cDNA with the couple of primers HK 3-HK 6 was inserted into the TA cloning plasmid. This cloned deleted insert was then cut with
Bcl I to obtain a 206 bp long fragment containing the nt 577–672 deletion. This fragment was ligated with pET-3d NH HK vector,2
 .previously digested with Bcl I to obtain the plasmid termed pET-3d NH HKdel. b pET-3d NH HKdel was cut with XbaI and NcoI:2 2
the 1302 bp fragment, containing the 96 bp deletion, was then recloned into the pET-3a HK expression vector, from which the
 .corresponding wild-type undeleted fragment 1398 bp long had been removed. The final expression vector was named pET-3a HKdel.
Further details of these procedures are reported in Section 2.
( )M. Bianchi et al.rBiochimica et Biophysica Acta 1360 1997 211–221216
tion experiments were initially performed according
to the instructions of the manufacturers. The opti-
mization of the recombinant human hexokinase ex-
pression in prokaryotic cells using the pET system as
well as the selected temperature of induction are
w xdescribed in 16 . Also the preparation of bacterial
extracts for hexokinase activity and protein assays
w xwas as reported in 16 .
2.7. Purification of recombinant wild-type human
hexokinase type I
The purification of recombinant wild-type human
hexokinase type I was performed as described previ-
w xously 16 with some modifications. Briefly, after
ammonium sulfate fractionation the pellet was resus-
pended in 10 ml of HIC buffer 5 mM sodium
potassium phosphate buffer, pH 7.55, containing 5
mM glucose, 3 mM 2-mercaptoethanol and 30%
 . .wrv ammonium sulfate and submitted to Hy-
drophobic Interaction Chromatography, using a
 .Phenyl Sepharose CL-4B column 1.8=13 cm . Elu-
tion was performed with a linear gradient of ammo-
nium sulfate from 30 to 0% 500 ml in each cham-
.ber . Fractions containing hexokinase activity were
collected, dialyzed, concentrated and directly loaded
onto a Blue-A column. The dye-ligand chromatogra-
w xphy step was performed as previously reported 16 ,
with the exception that washing and elution buffers
contained 90 mM KCl instead of 25 mM.
2.8. Hexokinase assay
Hexokinase activity was measured at 378C spec-
trophotometrically in a system coupled with glucose
 .6-phosphate dehydrogenase G6PD; EC 1.1.1.49 or,
in the Glc 6-P inhibition studies, in a coupled enzyme
 .system with pyruvate kinase PK; EC 2.7.1.40 and
 .lactate dehydrogenase LDH; EC 1.1.1.28 as de-
w xscribed in 17 . One unit of hexokinase activity is
defined as the amount of enzyme which catalyzes the
formation of 1 mmol of Glc 6-P or ADPrmin at
378C. Kinetic studies were performed in 100 mM
w xTris-HCl, pH 7.2 17 .
2.9. Determination of protein
Protein concentration was determined using the
w xBradford method 18 with bovine serum albumin as
standard, or spectrophotometrically by measuring the
absorbance of solutions at 280 nm against appropriate
blanks.
2.10. SDS-PAGE and immunoblotting
SDS-PAGE of the expressed wild-type and mutant
human HK I was performed in 14% polyacrylamide
w xgels according to the method of Laemmli 19 , while
Western blot analysis was carried out exactly as
w xdescribed in 20 .
2.11. Solid phase assay
Bacterial extracts in SDS sample buffer were incu-
bated at 1008C for 5 min, then diluted at the final
concentration of 0.4 mgrml in 150 mM NaCl. A
sample of human wild-type recombinant hexokinase,
 .purified to homogeneity 150 Urmg protein , was
treated as above with the exception that the final
concentration was 0.04 mgrml. Appropriate further
dilutions were made with the same buffer containing
 .0.02% wrv SDS so that the signal obtained after
staining for hexokinase was linear with the amount of
sample applied and was within the range of hexoki-
nase amounts used as standard 0.062–0.015
.mgrwell . Fifty microliters volume for samples and
hexokinase standards were loaded onto PVDF mem-
 .brane 0.2 mm with the aid of a 96-well Minifold
 .apparatus Bio Rad . After 2 hours at room tempera-
ture the wells were rinsed with TBS 50 mM Tris-Cl
.pH 7.5 and 150 mM NaCl and drawn to near
dryness. The filter was then removed, blotted dry,
and fixed. Fixed blots were then immunochemically
stained for hexokinase using an immunoaffinity-iso-
lated rabbit anti-human hexokinase antibody ob-
.tained as in Ref. 20 and goat anti-rabbit peroxidase-
conjugate IgG as a secondary antibody. The detection
system was the enhanced chemiluminescence
 .Amersham . Quantitation of recombinant hexokinase
present in bacterial extracts was by densitometry at
492 nm of the resulting film. Absolute values were
obtained by comparison with a standard curve gener-
ated by plotting the desitometric values of known
amounts of hexokinase standard applied to the same
filter.
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3. Results
3.1. Expression and characterization of wild-type
human recombinant hexokinase I
The expression of native recombinant human hex-
okinase in transformed bacterial culture was induced
by the addition of IPTG at a final concentration of
0.4 mM. After induction an aliquot of bacterial cells
was used for preparation of bacterial extracts as
w xdescribed in 16 . 20 mg of soluble cellular proteins
were separated by SDS-PAGE and stained with
Coomassie Blue. Induction with IPTG resulted in the
appearance of a prominent protein of about 100 kDa
which migrated at the same position as purified hu-
man placenta hexokinase type I; it was not present in
  .the induced control cells i.e. E. coli BL21 DE3
cells transformed with the plasmid pET-3a lacking
.the HK cDNA insert . Western blot analysis con-
firmed that the 100 kDa expressed protein was indeed
human hexokinase since it reacted with a monospe-
cific rabbit anti-human hexokinase type I antibody
 .data not shown . The highest specific activity value
was obtained by reduction of the induction tempera-
w xture from 378C to 228C for 15 h as detailed in 16 . In
 .these selected conditions E. coli cells BL21 DE3
transformed with the expression vector pET-3a HK
contained a biologically active hexokinase with a
specific activity of 2.00"0.26 Urmg of protein,
corresponding to a concentration of 13.2 " 2.7
HKUrml, whereas induced control cells had a hex-
okinase specific activity of only 0.088"0.02 Urmg
of protein, corresponding to a concentration of 0.43
"0.05 HKUrml of bacterial lysate. The wild-type
human recombinant hexokinase was purified to ho-
mogeneity as described in Section 2. Table 1 summa-
rizes the purification steps and indicates the average
 .  .Fig. 3. SDS-PAGE A and Immunochemical detection B of
wild-type, Leu529 to Ser mutant and 96 bp deleted recombinant
hexokinases. 20 mgs of soluble post-induction cell proteins from
 .bacterial cells transformed with pET-3a HK plasmid lane 1 ,
 . pET-3a HKm1667 plasmid lane 2 , pET-3a HKdel plasmid lane
.  .3 and pET-3a plasmid alone lane 4 were submitted to SDS-
 .PAGE and Coomassie staining A or electroblotted as described
w x  . in 20 B . Position of molecular weight markers with corre-
.sponding M in kDa are indicated on the left. The blot wasr
probed with an immunoaffinity-isolated rabbit anti-human hexok-
inase type I IgG and immunoreactive bands were visualized by
horseradish-peroxidase-labelled goat anti-rabbit IgG antibodies,
followed by ECL chemiluminescence detection.
yield from approx 10 preparations. The homogeneous
enzyme was further characterized for its kinetic and
regulatory properties in parallel with hexokinase type
Table 1
Purification of wild-type human hexokinase type I expressed in E. coli
 .  .  .  .Purification steps Total act. U Spec. act. Urmg Recovery % Purification fold
Cell-free extract 1250 2.0 100 1.0
 .Ammonium sulfate 70% of DEAE peak 725 11.0 58 5.5
Hydrophobic interaction chromatography 475 42.0 38 21.0
Blue A dye-ligand chromatography 325 150 26 75
All values are means of approx. 10 different experiments.
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Table 2
Kinetic properties of recombinant wild-type human hexokinase and placental hexokinase type I
Property Wild-type recombinant Placental hexokinase
hexokinase type I type I
 .K mM for MgPATP 1.40"0.20 0.90"0.10m
 .K mM for glucose 64.5"6.0 60.0"5.8m
 .K mM for Glc 6-P 28.5"3.0 30.0"4.0i
 .K mM for Glc 1,6-P 54.0"5.1 47.0"5.0i 2
Removal of Glc 6-P and Yes Yes
Glc 1,6-P inhibition by 2.0 mM P2 i
 .The K for MgPATP was determined at saturating glucose concentration 5 mM , while the K for glucose was derived at saturatingm m
 .  .MgPATP concentration 5 mM . The K values were determined with MgPATP as the varied substrate 0.5–2.0 mM at 5 mM-glucosei
concentration by a replot of slopes, obtained from double reciprocal plots, versus inhibitor concentrations. The patterns all indicated
competitive inhibition. All the experiments were performed in 100 mM Tris-HCl, pH 7.2, at 378C. The removal of Glc 6-P and Glc 1,6-P2
w xinhibition by P was evaluated as in 17 . The values are means"S.D. of three experiments.i
w xI purified from human placenta 21 . The apparent
K for MgPATP of the wild-type recombinant en-m
zyme was 1.4 mM and that of the placental enzyme
0.9 mM. Both enzymes are inhibited competitively
with respect to MgPATP by glucose 6-phosphate
 .  .Glc 6-P and glucose 1,6-bisphosphate Glc 1,6-P2
with removal of the inhibition by phosphate Table
.2 . Inhibition of wild-type recombinant HK by these
two phosphorylated sugars was non-competitive with
 .respect to glucose results not shown .
3.2. Expression of the recombinant human hexoki-
( 529 )nase mutant Leu to Ser and of the 96 bp deleted
mutant
pET-3a HKm1667 expression vector and pET-3a
 .HKdel plasmid were transformed into BL21 DE3 E.
coli strain. The induction procedure was as described
for wild-type human HK I as was the preparation of
bacterial extracts used for hexokinase activity and
protein assays. The specific activities of hexokinase
 .in extracts from induced BL21 DE3 cells trans-
formed with pET-3a HKm1667 and pET-3a HKdel
are shown in Table 3. The comparison of mutant and
wild-type hexokinase specific activities in bacterial
extracts suggests that while the site-directed change
T1667 “C was responsible for the complete loss of
hexokinase catalytic activity, the 96 bp deletion cor-
.responding to amino acids 166-197 of HK I caused a
drastic reduction in the activity. Attempts to obtain
some measurable hexokinase activity in pET-3a
HKm1667 transformed cells by changes in tempera-
ture of induction, duration of induction and cell
density before induction provided values similar to
those reported in Table 3. SDS-PAGE and Western
blotting experiments using induced bacterial extracts
Table 3
 .Hexokinase specific activities in extracts from induced BL21 DE3 cells, transformed with different expression plasmids
 .BL21 DE3 transformed cells HK spec. act. HK spec. act.
 .  .Urmg of bacterial protein Urmg of immunoreactive protein
Induced pET-3a 0.088"0.02 r
Induced pET-3a HK 2.00 "0.26 150"7.5
Induced pET-3a HKm1667 0.095"0.02 3.5"0.4
Induced pET-3a HKdel 0.350"0.06 12.3"0.7
w xThe determinations of hexokinase specific activities were performed on bacterial lysates prepared as described in 16 . The amount of HK
immunoreactive protein in cell lysates was obtained by a solid phase immunoassay as reported under Section 2. All values are
means"S.D. of five experiments.
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confirmed that indeed both recombinant proteins are
expressed in soluble form in the bacterial cells Fig.
.3 . However, since different recombinant proteins can
be expressed at different levels in E. coli cells
andror the efficiency of induction with IPTG could
vary from one experiment to another the expression
of the specific activity of hexokinase as units per mg
of total protein could be inappropriate. For this rea-
son, the activity of the recombinant hexokinases ex-
pressed as the difference between total and endoge-
.nous hexokinase activity was normalized to im-
munoreactive hexokinase protein as determined by
the solid phase immunoassay. This method allows for
direct comparison between wild-type and mutant re-
combinant hexokinases and also for the exclusion of
the interfering endogenous enzyme which is not rec-
 .ognized by the antibody used not shown . The spe-
cific activity values given as units of HK per mg of
 .immunoreactive protein Table 3 clearly indicate
that, while the Leu529 to Ser mutation completely
abolished the HK catalytic activity, the 96 bp deletion
drastically reduced the activity of the enzyme.
4. Discussion
The only clinical manifestation of hexokinase defi-
w xciency appears to be hemolytic anemia 22 . The
reasons why impairment of an important step in
glucose utilization has only this consequence at the
clinical level are still unknown: one possibility is that
the HK reaction is catalyzed by four isozymes, as
stated in the Section 1, and therefore only tissues
strongly dependent on only one isozyme could be
affected by such a mutation. Hexokinase in the ery-
throcytes is of central importance because it is one of
the rate-limiting steps in anaerobic glycolysis, the
only pathway by which ATP is produced in these
cells. Only 14 cases of hexokinase deficiency have
w xbeen described so far 7 and the only patient for
which the enzymatic defect of HK type I has been
investigated at the molecular level is a double het-
erozygote carrying a T“C substitution at nt 1667 on
one HK type I allele and a 96 bp deletion on the
w xother allele 11 . To investigate whether the two
mutations found in the ‘HK-Melzo’ cDNA were re-
ally responsible for the hexokinase deficiency, we
have now expressed in E. coli the two mutant hexok-
1667 inases carrying the T “C substitution which
529 .causes the amino acid change from Leu to Ser
and the 96 bp deletion, respectively, and then com-
pared their properties with those of the wild-type
human recombinant hexokinase type I. The wild-type
human recombinant HK is expressed in bacterial cells
as a soluble catalytically active protein that, upon
purification to homogeneity, shows the same kinetic
and regulatory properties of human placenta HK type
w xI 21 . Both mutant hexokinases were also expressed
as soluble proteins under the same conditions and the
hexokinase specific activity was measured in the
soluble bacterial extracts. The results obtained show
that while the 96 bp deleted hexokinase is only
partially active, the Leu529 to Ser mutant is com-
pletely inactive. Thus, we conclude that the hexoki-
nase catalytic activity is abolished when the non-polar
amino acid residue Leu529 is replaced by the polar
Ser and is strongly affected when the 96 bp deletion,
corresponding to the amino acid residues 166–197 in
the HK type I, is introduced. Since the three-dimen-
sional structure of HK type I and the organization of
its gene are not known, we can only refer to other
evolutionarily correlated enzymes such as yeast hex-
w x w xokinase 23 and human glucokinase 24 for which
the gene structure has been reported. Due to the high
degree of homology of the three hexokinases men-
tioned above, we have tentatively placed the 96 bp
deletion within amino acids 162 to 193 of human
w xglucokinase, which include all exon 6 24 , suggest-
ing that it may occur by aberrant splicing. The 96 bp
deletion removes a portion of the N-terminal half of
hexokinase type I, comprising the amino acid residues
from 166 to 197. Since previous results from our
w xlaboratory 20 and considerable evidence in the liter-
w xature 14,25,26 suggest that the catalytic site of HK
type I is located in the C-terminal domain of the
enzyme and that the N-terminal half is devoid of any
catalytic activity, the low activity found in the mutant
deleted HK was unexpected. However, although the
kinetic and regulatory properties of the isolated C-
terminal half of HK are very similar, if not identical,
to those of the native enzyme, a role for the N-termi-
nal region of hexokinase I in maintaining the proper
conformation of the full-length HK cannot be ex-
cluded. In previous studies on the ‘HK-Melzo’ vari-
ant, we found that the residual enzyme activity in the
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Fig. 4. Comparison of partial hexokinase and glucokinase amino
 .acid sequences see also Ref. 1 . Sequences compared are: b1,
bovine type I; h1, human type I; m1, murine type I; I, rat type I;
II, rat type II; III, rat type III; hIV, human type IV; IV, rat type
IV; sm, hexokinase from Schistosoma mansoni; ygk, yeast glu-
cokinase; yst, yeast hexokinase isozymes A and B the sequence
shown is that of the A isozyme, with residues that differ in the B
.isozyme shown immediately below . The arrow marks the Leu
residue which is conserved in all these hexokinases so far se-
quenced this Leu residue corresponds to the amino acid 529 in
.the human HK type I .
erythrocytes of the patient was about 20% and there-
fore it could be argued that the 96 bp deletion in the
N-terminal half of the enzyme could generate an
improperly folded hexokinase protein with a reduced
catalytic activity. As regards the Leu529 “Ser muta-
tion, this change corresponds to a substitution of a
non-polar amino acid residue with a polar one. More-
over, this Leu529 residue is highly conserved in all
w xthe hexokinases 1 as reported in Fig. 4, which
shows the striking similarities in sequence between
all the isozymes of the hexokinase family. This Leu529
is placed within the b-sheet of the small domain of
w xyeast hexokinase 23,27–29 which is known to un-
dergo major conformational changes during substrate
binding. In particular, the conformational change from
the ‘open’ to the ‘closed’ form, induced by glucose is
considered to be a necessary step for catalysis and
thus it can be supposed that even the substitution of
only one residue may impair the enzyme catalytic
function. Additional crystallographic studies will cer-
tainly be necessary to further support these conclu-
sions. However, our results provide direct evidence
that the amino acid substitution Leu529 “Ser and the
96 bp deletion found in human hexokinase deficiency
are responsible for the impairment of catalytic activ-
ity found in the only case in which a hexokinase
defect has been investigated at molecular level so far.
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